Changes in spatiotemporal gait parameters following intravenous immunoglobulin treatment for chronic inflammatory demyelinating polyneuropathy

• Published in: Muscle & nerve Vol. 56; no. 4; pp. 732 - 736
• Main Authors: Vo, Mary L., Chin, Russell L., Miranda, Caroline, Latov, Norman
• Format: Journal Article
• Language: English
• Published: United States Wiley Subscription Services, Inc 01.10.2017
• Subjects: Administration, Intravenous; Aged; chronic inflammatory demyelinating polyneuropathy; CIDP; Demyelination; Embedded sensors; Embedded systems; Female; Gait; Gait - drug effects; Gait - physiology; gait analysis; Grip strength; Humans; Immunoglobulins; Immunoglobulins, Intravenous - administration & dosage; Inflammation; Intravenous administration; intravenous immunoglobulin; Male; Measurement methods; Medical research; Middle Aged; Neuropathy; outcome measures; Patients; Polyneuropathy; Polyradiculoneuropathy, Chronic Inflammatory Demyelinating - diagnosis; Polyradiculoneuropathy, Chronic Inflammatory Demyelinating - drug therapy; Polyradiculoneuropathy, Chronic Inflammatory Demyelinating - physiopathology; Prospective Studies; Spatial Behavior - drug effects; Spatial Behavior - physiology; spatiotemporal gait parameters; Time Factors; Treatment Outcome; Velocity; chronic inflammatory demyelinating polyneuropathy; spatiotemporal gait parameters; outcome measures; CIDP; intravenous immunoglobulin; gait analysis
• ISSN: 0148-639X; 1097-4598
• DOI: 10.1002/mus.25553

ABSTRACT Introduction Gait impairment is a common presenting symptom in patients with chronic inflammatory demyelinating polyneuropathy (CIDP). However, gait parameters have not previously been evaluated in detail as potential independent outcome measures. Methods We prospectively measured changes in spatiotemporal gait parameters of 20 patients with CIDP at baseline and following treatment with intravenous immunoglobulin (IVIG), using GAITRite® a computerized walkway system with embedded sensors. Results Overall, study patients showed significant improvements in gait velocity, cadence, stride length, double support time, stance phase, and swing phase following IVIG treatment. Mean changes in velocity, stance phase, and swing phase, exhibited the greatest statistical significance among the subgroup that exhibited clinically meaningful improvement in Inflammatory Neuropathy Cause and Treatment disability score, Medical Research Council sum score, and grip strength. Conclusions Assessment of gait parameters, in particular velocity, step phase and swing phase, is a potentially sensitive outcome measure for evaluating treatment response in CIDP. Muscle Nerve 56: 732–736, 2017